北陆药业(300016) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was CNY 145,560,939.49, a decrease of 43.13% year-on-year[3]. - The net profit attributable to shareholders for Q3 2021 was CNY 13,264,783.86, down 80.76% compared to the same period last year[3]. - The net profit after deducting non-recurring gains and losses was CNY 1,320,272.02, a decline of 97.97% year-on-year[3]. - Total operating revenue for the current period reached ¥680,836,560.47, an increase of 9.1% compared to ¥623,551,564.18 in the previous period[29]. - The company's net profit attributable to shareholders increased to ¥916,228,595.04 from ¥815,934,348.47, a growth of 12.3%[28]. - The net profit for the current period is 122,069,471.17, a decrease of 19.2% compared to 150,800,273.56 in the previous period[30]. - The total profit for the current period is 137,069,838.77, down from 170,924,584.11 in the previous period[30]. - The operating profit for the current period is 141,140,413.13, a decrease from 174,565,382.40 in the previous period[30]. - The total comprehensive income attributable to the parent company owners is 129,677,202.02, down from 160,456,123.17 in the previous period[30]. Cash Flow and Assets - The operating cash flow for the year-to-date period increased by 35.09% to CNY 152,132,123.63[5]. - The cash flow from operating activities net amount is 152,132,123.63, an increase of 35.1% compared to 112,619,157.09 in the previous period[33]. - The cash flow from investing activities shows a net outflow of -511,659,837.06, worsening from -91,671,402.73 in the previous period[35]. - The cash flow from financing activities resulted in a net outflow of -111,176,875.83, compared to a net inflow of 120,396,145.25 in the previous period[35]. - The cash and cash equivalents at the end of the period were CNY 55,438,470.00, a decrease of 45.31% from the beginning of the period[10]. - The company's cash and cash equivalents decreased to ¥554,384,715.16 from ¥1,013,727,678.06, a decline of 45.6%[25]. - The cash and cash equivalents at the end of the period amount to 525,183,317.32, compared to 389,553,993.86 at the end of the previous period[35]. - The total assets at the end of the reporting period were CNY 2,906,673,470.06, an increase of 2.08% from the end of the previous year[5]. - Total assets rose to ¥2,906,673,470.06, compared to ¥2,847,573,506.75, an increase of 2.1%[28]. Liabilities and Shareholder Information - The total liabilities decreased to ¥916,285,173.38 from ¥955,500,130.72, a decline of 4.1%[27]. - The total number of common shareholders at the end of the reporting period is 31,562[15]. - The largest shareholder, Wang Daixue, holds 21.82% of the shares, totaling 107,537,613 shares, with 30,546,030 shares pledged[15]. - The top ten shareholders hold a significant portion of the shares, with the first three shareholders collectively owning over 33%[15]. - The company has a total of 86,098,375 shares under lock-up agreements, primarily due to executive stock options[19]. - The company plans to issue up to 9.1 million shares, expecting to raise no more than 109.2 million yuan for repaying bank loans[22]. Operational Insights - The company reported a significant decrease in sales of its diabetes product and contrast agent due to national procurement policies, impacting revenue[9]. - Inventory at the end of the period increased by 74.18% to CNY 20,399,630.00, attributed to raw material and product stockpiling[10]. - Inventory increased significantly to ¥203,996,299.45 from ¥117,118,440.22, representing a growth of 74.0%[25]. - Research and development expenses were ¥32,218,332.46, slightly down from ¥33,398,300.06 year-over-year[29]. - The company plans to expand its production capacity with ongoing investments in new projects, including a production line for iodine contrast agents[11]. Financial Instruments and Corporate Governance - As of September 30, 2021, the remaining convertible bonds amount to 4,993,363 with a total face value of 499,336,300 yuan[21]. - The company’s subsidiary, Haichang Pharmaceutical, completed the third board and supervisory board re-election on October 13, 2021[22]. - The company’s stock options for executives are subject to a 25% annual transfer limit during their tenure and six months after[18]. - The company’s subsidiary, Haichang Pharmaceutical, passed the consistency evaluation for the quality and efficacy of Gadopentetic Acid Injection in July 2021[20]. - The company’s stock issuance has been approved by the shareholders' meeting and is awaiting further regulatory approvals[22].